Document is current
Any future updates will be listed below
-
Authors
Inaba, Hiroshi https://orcid.org/0000-0003-4373-5050
Nishikawa, Satomi
Shinozawa, Keiko
Shinohara, Sho
Nakazawa, Fumie
Amano, Kagehiro
Kinai, Ei
- License Information
-
More Information
Article History
Received: 21 July 2021
Revised: 29 October 2021
Accepted: 29 October 2021
First Online: 9 November 2021
Declarations
:
: H. Inaba received funding for this research work from Sysmex and speaker honoraria from Sanofi and CSL-Behring. S. Nishikawa, S. Shinohara, and F. Nakazawa are employees of the Sysmex Corporation. K. Shinozawa was an endowed assistant professor funded by Baxter/Baxalta/Shire and CSL-Behring (until March 2020). K. Amano received research funding from KM Biologics. Moreover, this author received a consulting fee from Chugai Pharmaceutical, received payment for lectures on speakers’ bureaus from Chugai Pharmaceutical, Sanofi, Bayer, Takeda Pharmaceutical, Novo Nordisk, CSL Behring, KM Biologics, Pfizer, and Japan Blood Products Organization, and is listed as an entity’s board of directors or advisory committee member for Chugai Pharmaceutical. E. Kinai received research grants from Chugai Pharmaceutical, and CSL-Behring. Moreover, this author received honoraria from Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Chugai Pharmaceutical, Novo Nordisk, and CSL-Behring.
